T1DM

14 registered clinical trials studyying T1DM — 7 currently recruiting.

Status	Trial	Sponsor	Phase
Not Yet Recruiting	Pediatric Insulin Plan Calculator for T1DM Management NCT07427134	Sultan Qaboos University	N/A
Not Yet Recruiting	A Clinical Trial Using Tirzepatide to Help Adults With Type 1 Diabetes Automatically Control Their Blood Sugar NCT07284511	Melissa-Rosina Pasqua	Phase 2 / Phase 3
Recruiting	A Study to Investigate Safety and Effectiveness of Porcine Pancreatic Cells (OPF-310) in Patients With Type 1 NCT06575426	Otsuka Pharmaceutical Factory, Inc.	Phase 1 / Phase 2
Recruiting	CNP-103 in Adolescent and Adult Subjects Ages 12-35 With Recently Diagnosed (Within 6 Months) Stage 3 Type 1 D NCT06783309	COUR Pharmaceutical Development Company, Inc.	Phase 1 / Phase 2
Not Yet Recruiting	Influence of Circadian Clock on Hormonal, Metabolic, Neurocognitive Markers in Adolescents With and Without Di NCT04054934	Assaf-Harofeh Medical Center	—
Unknown	RCT for Evaluation of Insulin Administration,While Using the iPORT System NCT04421001	Assaf-Harofeh Medical Center	N/A
Recruiting	Efficacy of Hyperbaric Oxygen Therapy (HBOT) in New-onset Type-1 Diabetes Mellitus NCT04412200	Assaf-Harofeh Medical Center	N/A
Withdrawn	Glycemic Control and Quality of Life With i- Port Advance in Pediatric T1DM NCT04428762	Assaf-Harofeh Medical Center	N/A
Completed	Health-related Quality of Life and Psychosocial Aspects of Diabetes Technology (Insulin Pumps) NCT04756011	Ain Shams University	—
Completed	Brain Health and Development With T1DM NCT03335878	Washington University School of Medicine	—
Recruiting	Type 1 Diabetes Extension Study NCT02734277	National Institute of Allergy and Infectious Diseases (NIAID)	—
Completed	The Use of Topical Nasal Steroids for Skin Reactions to Continuous Glucose Monitoring System, Among Children a NCT03594565	Assaf-Harofeh Medical Center	EARLY_Phase 1
Completed	Glycemic Control and Treatment Satisfaction in Children With Type 1 Diabetes Using Insulin Pumps NCT03697369	Assaf-Harofeh Medical Center	—
Completed	Tocilizumab (TCZ) in New-onset Type 1 Diabetes NCT02293837	National Institute of Allergy and Infectious Diseases (NIAID)	Phase 2